Article Details

Roivant extends AI drug discovery reach with $450M Silicon Therapeutics buyout

Retrieved on: 2021-02-26 18:56:15

Tags for this article:

Click the tags to see associated articles and topics

Roivant extends AI drug discovery reach with $450M Silicon Therapeutics buyout. View article details on hiswai:

Excerpt

The protein degradation platform is driven by Roivant's proprietary VantAI technology, which applies machine-learning techniques to data. So far, the ...

Article found on: medcitynews.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up